Verification evidence is still being completed.
PDF / print export
Nanoform Finland
Helsinki, Finland
- Verified lead
- Edward Haeggstrom
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Nano-crystallization
- Review cycle
- May 2026
- Full address
- Cultivator II, Viikinkaari 4, FI-00790 Helsinki, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Nanoform governance page confirming Edward Haeggstrom as CEO.
- Editorial note
- Nanoform's governance and February 2026 release keep Edward Haeggstrom in the verified leadership layer.
Nano-crystallization
GMP Certified
Nanoform's governance and February 2026 release keep Edward Haeggstrom in the verified leadership layer.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Nanoform's governance and February 2026 release keep Edward Haeggstrom in the verified leadership layer.
- Lead
- Edward Haeggstrom (verified ↗)
- Address
- Cultivator II, Viikinkaari 4, FI-00790 Helsinki, Finland (source ↗)
- Compliance
- GMP Certified
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Clinical to Commercial
- Capabilities
- C3 Nano-technology · Drug Solubility Enhancement · Particle Engineering
- Founded
- 2015
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Edward Haeggstrom
Chief Executive Officer
Full addressCultivator II, Viikinkaari 4, FI-00790 Helsinki, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Nanoform contact page listing Cultivator II, Viikinkaari 4, Helsinki.
Open sourceClinical to Commercial
Helsinki, Finland. Nano-crystallization. Review completed on 14 Mar 2026.
Fimea / FDA
GMP Certified
Nano-crystallization
Nanoform's governance and February 2026 release keep Edward Haeggstrom in the verified leadership layer.
Editorial note
Nanoform's governance and February 2026 release keep Edward Haeggstrom in the verified leadership layer.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
C3 Nano-technology
Drug Solubility Enhancement
Particle Engineering
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Proprietary Nanoform Skids
SEM Hub
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Nanoform Finland located?
- Nanoform Finland operates from Cultivator II, Viikinkaari 4, FI-00790 Helsinki, Finland, Helsinki, Finland.
- Who runs Nanoform Finland?
- Nanoform Finland is led by Edward Haeggstrom, Chief Executive Officer. Verified 14 Mar 2026.
- What certifications does Nanoform Finland hold?
- Nanoform Finland is documented under GMP Certified.
- What does Nanoform Finland do?
- Nanoform's governance and February 2026 release keep Edward Haeggstrom in the verified leadership layer. Core capabilities: C3 Nano-technology, Drug Solubility Enhancement, Particle Engineering.
Editorial context
Related technical briefs
Briefs that name Helsinki as a covered market or city.